Status:
COMPLETED
Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
Lead Sponsor:
Sunnybrook Health Sciences Centre
Conditions:
Prostate Cancer
Eligibility:
MALE
18-75 years
Phase:
PHASE4
Brief Summary
The Acute Pain Service (APS) at Sunnybrook has been using Gabapentin 200 mg three times a day (TID) resulting in anecdotal benefits in terms of analgesia and opioid sparing effects. Higher doses of Ga...
Detailed Description
Gabapentin Gabapentin is an anti-epileptic agent originally developed to treat spasticity (1), and eventually was found to be effective against chronic neuropathic pain (1,2). Gabapentin is available ...
Eligibility Criteria
Inclusion
- Undergoing radical prostatectomy
- Able to read and write english (assistance is allowed)
- Normal creatinine blood serum level
- No known allergies to study medications
Exclusion
- Patients not providing informed consent
- Patients less than 18 years of age or greater than 75 years of age
- Known allergy to any of the medications being used
- History of drug or alcohol abuse
- Preoperative pain
- Patients unable or unwilling to use PCA
- Patients with impaired renal function (Creatinine \>106)
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00982800
Start Date
June 1 2007
End Date
January 1 2010
Last Update
August 6 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Center
Toronto, Ontario, Canada, M5V 2W8